Indoco Remedies Ltd Share Price Today - Indoco Remedies Ltd Stock Price Live NSE/BSE

Indoco Remedies Ltd

NSE: INDOCO BSE: 532612

₹192.20

(1.80%)

Thu, 26 Mar 2026, 05:41 am

MTF 5xInvest in Indoco Remedies Ltd with 5x Leverage Buy with MTF

Market Cap17.66B

PE Ratio0

Dividend0.10

Health Technology

Pharmaceuticals: Major

24.5K

Indoco Remedies Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
1706.69
Net Profit
-77.95
P/B
2.11
Sector P/E
31.48
P/E
0
EV/EBITDA
29.60
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
9.79
ROCE (Industry)
12.90
RONW (Industry)
12.30
ROE
-7.31
ROCE
-0.42
Debt/Equity
0.78
EPS (TTM)
0
Dividend Yield
0.11
Book Value
106.15
Interest Cover
-0.12

Analysis

all

Pros

Indoco Remedies's earnings are expected to grow significantly at over 20% yearly.
Indoco Remedies's earnings growth is expected to exceed the India market average.
Indoco Remedies's earnings growth is expected to exceed the low risk savings rate of 7.2%.
Indoco Remedies's earnings are expected to exceed the low risk growth rate next year.
Indoco Remedies's net income is expected to increase by more than 50% in 2 years time.

Cons

Indoco Remedies is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
No need to calculate the sustainability of Indoco Remedies's dividends as it is not paying a notable one for India.
Indoco Remedies is not paying a notable dividend for India, therefore no need to check if the payments are stable.
Indoco Remedies's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Indoco Remedies's dividend is below the markets top 25% of dividend payers in India (3.08%).

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	58.90	58.90	58.90	58.90	58.80
FII	1.10	1.25	1.22	1.24	1.25
DII	18.15	18.16	18.96	18.75	18.90
Public	21.85	21.69	20.92	21.11	21.06
Government	0	0	0	0	0

Technical Analysis

RSI

38.20

MACD

-5.55

50 DMA

204.37

200 DMA

261.25

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	335.09	276.09	239.19	217.09	180.19	158.09	99.09
Fibonacci	276.09	253.56	239.63	217.09	194.56	180.63	158.09
Camarilla	218.50	213.10	207.69	217.09	196.87	191.46	186.06

Pivots Level: Classic

+118.00

335.09

+59.00

276.09

+22.09

239.19

217.09

Pivot Point

LTP: 185.90

-36.91

180.19

-59

158.09

-118

99.09

Moving Average

SMAEMA

Period

Value

10-EMA
189.67
20-EMA
193.85
30-EMA
197.66
50-EMA
205.42
100-EMA
223.00
200-EMA
244.95

Announcement Date	Purpose	Action	Ex Date
03 Feb 2026	board-meetings	Quarterly Results
06 Nov 2025	board-meetings	Quarterly Results, Half Yearly Results
14 Aug 2025	agm
04 Aug 2025	dividend	Final Dividend - Rs. - 0.2	04 Sept 2025
22 May 2025	dividend	₹0.20 Dividend /Share	04 Sept 2025
30 Aug 2024	agm
19 Aug 2024	dividend	Annual General Meeting/Dividend - Rs 1.50 Per Share	20 Sept 2024
16 May 2024	dividend	₹1.50 Dividend /Share	19 Sept 2024
28 Aug 2023	agm
18 Aug 2023	dividend	Annual General Meeting/Dividend - Rs 2.25 Per Share	20 Sept 2023

Indoco Remedies Ltd

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Lupin Ltd

Indoco Remedies Ltd About

Indoco Remedies is engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients. The Company caters to both Domestic and International markets.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1947

Headquarters

CEO

Suresh G Kare

Employees

Contact

Website

http://www.indoco.com

compliance.officer@indoco.com

Phone

91-022-26541851-55

Location

Indoco House 166 C S T Road, Santacruz (East) Kalina, Mumbai, Maharashtra, 400098

Year	History
2020	Indoco wins major tenders in Germany for Allopurinol Tablets Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents Diclofenac & Quetiapine Indoco receives USFDA approval for Succinylcholine Chloride Injection USP Indoco receives USFDA approval for Olanzapine Tablets
2021	Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals
2022	Indoco Remedies to acquire stake in Kanakal Wind Energy. Indoco Remedies receives USFDA approval for Lacosamide Injection USP. Indoco Remedies receives USFDA approval for Lacosamide Tablets.
2023	Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets. Indoco acquires 85 % equity stake in US based FPP Holding Company, LLC. Indoco receives EIR for its manufacturing facility in Goa (Plant I).
2024	Indoco enters into a strategic distribution partnership with Clarity Pharma, UK. Indoco Remedies receives final ANDA approval from USFDA for Varenicline Tablets, 0.5 mg and 1 mg Indoco Remedies receives final ANDA approval from USFDA for Pregabalin capsules. Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets. USFDA successfully completes inspection at Indoco's API Kilo Lab manufacturing facility and IAS division without any observations.

Client Name	Order Side	QTY	Avg Price	Date
XTX MARKETS LLP	Buy	478901	507.94	12 Aug 2021
XTX MARKETS LLP	Sell	481713	508.51	12 Aug 2021
OHM JUNIPER LONGTERM FUND LTD	Sell	500000	265.31	02 Dec 2020
DOVETAIL INDIA FUND CLASS 6 SHARES	Buy	500000	265.31	02 Dec 2020
DSP AIF PHARMA FUND	Sell	1276434	140	10 Oct 2019
DSP MUTUAL FUND	Buy	1276434	140	10 Oct 2019
DSP BLCKROCK MUTUAL FUND	Sell	500000	190	07 Jun 2018
DSP BLACKROCK MUTUAL FUND	Sell	1000000	190.01	07 Jun 2018
INDIA WHIZDOM FUND	Sell	588800	280	24 Jan 2018
INDIA WHIZDOM FUND	Sell	500000	280.01	24 Jan 2018

Indoco Remedies Ltd News

Indoco Remedies to participate in Valorem Conference

Indoco Remedies' senior management will participate in the 11th Annual Valorem Conference on March 23, 2026, at Grand Hyatt, Santacruz (East) at 09:00 am.

13 Mar 2026

companies

Indoco Gets USFDA Nod for Brivaracetam Solution

Indoco Remedies receives final USFDA approval for Brivaracetam Oral Solution, expanding its pharmaceutical portfolio in the US market with this anti-epileptic medication.

24 Feb 2026

stocks

Indoco Remedies Q3 FY26 Results Show Mixed Performance

Indoco Remedies reported 6.8% revenue growth in Q3 FY26 with improved international business performance, though domestic formulations remained flat amid acute therapy challenges.

10 Feb 2026

co actions results

Indoco Remedies Q3 Net Loss Widens to ₹298M

Indoco Remedies reported a consolidated net loss of ₹298 million in Q3, compared to a loss of ₹264 million in the same quarter of the previous year, representing a year-on-year deterioration.

03 Feb 2026

co actions results

Indoco Remedies Office Inspected by GST Officials

GST officials conducted inspection at Indoco Remedies' office premises. The pharmaceutical company is cooperating with the ongoing investigations by providing necessary assistance to authorities.

03 Feb 2026

stocks

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800